Holen Sie sich die Stockscreener-App
2.71
4.23%
0.11
Vorhandelsmarkt:
2.71
Black Diamond Therapeutics Inc Aktie (BDTX) Neueste Nachrichten
What drives Black Diamond Therapeutics Inc stock priceReal Estate Investment Trusts & Download Your Free Wealth Map PDF - earlytimes.in
Evoke Pharma Leads Stock Performance with 148.87% Return in Pharmaceuticals Sector - Markets Mojo
Black Diamond Therapeutics’ Silevertinib shows 60% response rate in preliminary phase 2 lung cancer data - MSN
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Black Diamond Therapeutics’ Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Insider Monkey
What analysts say about Black Diamond Therapeutics Inc stockCandlestick Trading Patterns & High Return Trading Ideas - earlytimes.in
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to NASDAQ Biotechnology Index - marketscreener.com
Why Black Diamond Therapeutics Inc. stock could benefit from AI revolutionTrade Analysis Report & AI Based Buy/Sell Signal Reports - Улправда
BDTX (Black Diamond Therapeutics) EV-to-OCF : 1.30 (As of Dec. 21, 2025) - GuruFocus
Can Black Diamond Therapeutics Inc. stock deliver strong Q4 earnings2025 Institutional Moves & Daily Market Momentum Tracking - DonanımHaber
What margin trends mean for Black Diamond Therapeutics Inc. stockMarket Performance Recap & Verified Short-Term Trading Plans - DonanımHaber
Can Black Diamond Therapeutics Inc. stock withstand economic slowdown2025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда
What momentum indicators show for Black Diamond Therapeutics Inc. stockWeekly Stock Summary & Accurate Trade Setup Notifications - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Cullinan Management (CGEM) - The Globe and Mail
Black Diamond Therapeutics (BDTX) director receives 4,665 share award - Stock Titan
Black Diamond Therapeutics (BDTX) – Analysts’ Weekly Ratings Updates - Defense World
A strong week for data readouts: Clinical Report - BioCentury
Can Black Diamond Therapeutics (BDTX) Turn Silevertinib’s Dual-Cancer Ambition Into a Cohesive Strategy? - Yahoo Finance
Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX) - sharewise.com
Can Black Diamond Therapeutics Inc. stock continue upward trendGap Down & Long-Term Investment Growth Plans - Newser
Will Black Diamond Therapeutics Inc. stock attract more institutional investorsInsider Selling & Technical Pattern Based Buy Signals - Newser
Black Diamond Therapeutics (NASDAQ:BDTX) Stock Rating Lowered by Guggenheim - MarketBeat
Stifel reiterates Buy rating on Black Diamond Therapeutics stock at $8 - Investing.com Australia
Analyst Downgrades BDTX to Neutral from Buy | BDTX Stock News - GuruFocus
This PayPal Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
How Black Diamond Therapeutics Inc. stock reacts to oil pricesBond Market & Consistent Profit Trade Alerts - Newser
Black Diamond Therapeutics (NASDAQ:BDTX) Downgraded by Guggenheim to Neutral - Defense World
Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data - Sahm
Are Smart Investors Making the Right Decision? Black Diamond Therapeutics Inc (BDTX) - Setenews
US Stocks Mixed; Dollar Tree Posts Upbeat Earnings - Benzinga
Black Diamond Therapeutics announces preliminary Phase 2 data for Silevertinib in 1L NSCLC - marketscreener.com
Black Diamond Therapeutics (BDTX) Reveals Promising Phase 2 Tria - GuruFocus
Black Diamond Therapeutics Announces Preliminary Phase 2 - GlobeNewswire
Black Diamond to present Phase 2 silevertinib trial results By Investing.com - Investing.com Canada
Black Diamond to present Phase 2 silevertinib trial results - Investing.com India
Black Diamond Therapeutics to Host Webcast on Phase 2 Clinical Trial Results of Silevertinib on December 3, 2025 - Quiver Quantitative
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - The Manila Times
Black Diamond Therapeutics to Host Webcast Presentation - GlobeNewswire
Black Diamond Therapeutics, Inc. (BDTX) -9.9% in Intraday Trading: Decline Amid Routine Activity - Stocks Telegraph
Black Diamond Therapeutics (Nasdaq: BDTX) to present silevertinib Phase 2 trial results in Dec. 3 webcast - Stock Titan
Is Black Diamond Therapeutics Inc a good long term investmentCandlestick Trading Patterns & Learn to Trade with Real-Time Feedback - earlytimes.in
Adversity is less terrifying than hope: Black Diamond Therapeutics Inc (BDTX) - Setenews
Aug Retail: Why Black Diamond Therapeutics Inc. stock could benefit from AI revolutionTrade Volume Report & Expert Curated Trade Ideas - moha.gov.vn
Black Diamond Therapeutics Inc. (BDTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What insider trading reveals about Black Diamond Therapeutics Inc. stockQuarterly Profit Review & Fast Exit and Entry Strategy Plans - newser.com
Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout (NASDAQ:BDTX) - Seeking Alpha
Will Black Diamond Therapeutics Inc. stock pay special dividends2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):